SS-31 (Elamipretide) (50mg)
SS-31 (Elamipretide) targets the inner mitochondrial membrane, stabilizing cardiolipin. 50 mg vial — ideal for higher-dose or longer-duration protocols. Subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full SS-31 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
SS-31 binds to cardiolipin in the inner mitochondrial membrane, stabilizing respiratory complexes. It improves electron flow, increases ATP, reduces ROS, and prevents mitochondrial dysfunction.
Quick Start
- Reconstitution: Add 2.5 mL bacteriostatic water → 20 mg/mL.
- Typical dose: 5–20 mg daily.
- Easy measurement: At 20 mg/mL, 5 units = 1 mg.
- Storage: −20 °C / 2–8 °C after reconstitution.
Dosing Table — SS-31 50mg
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 5 mg | 25 Units (0.25 mL) |
| Weeks 3–4 | 10 mg | 50 Units (0.50 mL) |
| Weeks 5–8 | 20 mg | 100 Units (1.00 mL) |
Studies report administration once daily subcutaneously. Cycle 4–8 weeks.
Related compounds
Reconstitution Steps
- Draw 2.5 mL of bacteriostatic water.
- Inject slowly down the side of the vial.
- Gently swirl.
- Refrigerate at 2–8 °C.
Protocol Overview
- Goal: Mitochondrial restoration at higher doses.
- Schedule: Daily for 4–8 weeks.
Dosing Protocol
- Start: 5 mg/day × 2 weeks.
- Increase: 10 mg, then 20 mg/day.
- Cycle: 4–8 weeks.
- Break between cycles: After the cycle (4–8 weeks), a 4–6 week pause is recommended. SS-31 targets mitochondria — the pause prevents tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle (4–8 weeks), a 4–6 week pause is recommended. SS-31 targets mitochondria — the pause prevents tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C · use within 3 weeks.
Important Notes
- Larger injection volumes — may be split into 2 sites.
- Use sterile technique.
Potential Benefits & Side Effects
Potential Benefits:
- Enhanced mitochondrial function.
- Increased ATP production.
- Reduced oxidative stress.
- Cardioprotective effects.
Potential Side Effects:
- Mild injection site reaction.
- Generally very well tolerated.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Renal safety under evaluation
Elamipretide is being evaluated for renal mitochondriopathies. Phase 3 in Barth syndrome did not meet primary endpoint.
📄 Stealth BioTherapeutics — Phase 3 ResultsReferences
- JACC Heart Failure — Elamipretide in heart failure
View Source - Aging Cell — SS-31 reverses mitochondrial aging
View Source
Recommended Supplements
NMN (Nicotinamide Mononucleotide)
CoQ10 (Ubiquinol)
Vitamin E (Mixed Tocopherols)
External Sources & Regulatory Status
Regulatory Approvals
Elamipretide · Barth syndrome / Mitochondrial disorders (2020)
Barth syndrome (NCT05168774)
FDA Breakthrough Therapy
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →